Background: Among pathological hair loss conditions in men the androgenic alopecia (L64 according to ICD-10) has been the most common diagnosed. However, the reasons of the occurrence and development of the disease remain incompletely clarified, that determines the difficulties of personalized therapy. Aims: To analyze both genetic and non-genetic factors involved in the pathogenesis of androgenic alopecia in men, and to create personalized multifactorial model for description of individual causes of the disease. Materials and methods: The genetic predisposition to androgenic alopecia was estimated by the set of SNP rs929626, rs5919324, rs1998076, rs12565727 and rs756853, analyzed by mini-sequencing. The non-genetic factors included: hormones and metabolic markers, trace elements, and vitamins. Two-stage model creation of androgenic alopecia occurrence and development was carried out using a neural network (for genetic factors) followed by step-by-step linear discriminate analysis (for non-genetic factors). Results: The case-control study included 50 men revealing IIV stages of androgenic alopecia (according to Norwood-Hamilton classification) and 25 healthy volunteers relevant in their age and origin. The analysis of each SNP separately did not show significant differences between these groups, while SNP joint consideration in neural network model made it possible to assess the genetic predisposition to androgenic alopecia, as well as to divide the low and high genetic risk subgroups. A large number of significant non-genetic factors, including elevated levels of dihydrotestosterone, 17-OH-progesterone, insulin, and deficiency of Mg, Cu, Zn, Se, vitamins D, E, folic acid was shown in low genetic risk subgroup. In turn, in the high genetic risk subgroup the set of significant non-genetic factors was limited to metabolic and micronutrient disorders only. These data were used for the multifactorial model showing 81.285.1% accuracy being the most effective in early (III) stages of androgenic alopecia. Conclusions: The different influence of non-genetic factors in patients with low and high genetic risk of androgenic alopecia has been revealed. The integral factors consideration in the proposed two-stage multifactorial model identifies individual causes of the disease and gives the chance for the development of personalized therapy of androgenic alopecia in men.
Androgenic alopecia (AGA) is the most common type of progressive hair loss in man. The search for reliable predictors of the conservative treatment’s effectiveness is an urgent problem today. Forty-eight patients with AGA, stages I–IV by the Norwood–Hamilton scale, were treated for 4 months with 5% topical minoxidil joints with corrections for trace element and vitamin imbalances. In most cases, the positive therapy’s effect was shown in the parietal but not in the occipital area, whereas that effect was observed in others. The attempts to associate the therapy’s effectiveness with initially defined genetic, hormonal, and metabolic parameters showed the absence of differences between groups with positive and negative outcomes. Among the studied nutrient parameters (Zn, Cu, Mg, Ca, Fe, and Se, as well as vitamins B12, E, D, and folic acid), differences between these groups was shown in zinc content only. The starting point from a zinc plasma level above 10 µmol/L likely provides the success of the subsequent conservative therapy and correlates with an increase in the hair density and diameter in the parietal area. The integral predictive value of the Zn plasma level was assessed as 72.3% (positive predictive value: −88%; and negative predictive value: −55%).
The coronavirus disease pandemic (COVID-19) was announced by WHO in February 2020. In Moscow, the first case of the disease was detected on March 2, 2020 in a man who arrived from Italy. Two weeks after the first case, there was an exponential increase in the number of cases. The incidence peaked in the 19th week of the year, followed by a steady decline, lasting 16 weeks. Objective. To investigate the level and structure of population immunity to the SARS-CoV-2 virus among the population of Moscow against the background of the incidence of COVID-19. Patients and methods. The study of population immunity of Moscow residents to SARS-CoV-2 was carried out in the period from July 1, 2020 to July 30, 2020 against the background of stabilization of the incidence rate. The work was conducted as part of the first stage of the Rospotrebnadzor project to assess population immunity to the SARS-CoV-2 virus among the population of the Russian Federation, taking into account the protocol recommended by WHO. Volunteers for the study were selected by the method of questioning and randomization. The results of the survey of 2688 people were included in the analysis. The number of volunteers in all age groups was 384–385 people. The content of specific IgG to the SARS-CoV-2 nucleocapsid was determined by the enzyme-linked immunosorbent assya using a kit produced by FBIS SRCAMB according to the manufacturer's instructions. Results. During the survey of volunteers it was found that the share of seroprevalent residents of Moscow was 22.1%. By age groups, the highest proportion of seroprevalent was found among children aged 14–17 years (44.6%), the lowest (15.9%) – among people aged 18–29 years. Seroprevalence had no gender differences. The lowest level of herd immunity was revealed in the North-Western Administrative District (16.8%), the highest – in the South-Eastern Administrative District, as well as in the Troitsky and Novomoskovsky Administrative Districts of Moscow (in both, 24.1%). The smallest number of seropositive persons was among cultural workers (5.8%), the largest – among medical workers (27.0%). In the presence of contacts with patients with COVID-19, the probability of seroconversion increases by 1.5 times, and among convalescing persons COVID-19 antibodies were detected in 60.0% of cases. The proportion of people with asymptomatic infection among seropositive residents was 82.4%. Conclusion. The results obtained make it possible to characterize the population immunity of Moscow residents and are essential for the planning and implementation of anti-epidemic measures during the incidence of COVID-19. Key words: coronaviruses, SARS-CoV-2, seroprevalence, population, COVID-19
A pandemic of the disease caused by the SARS-CoV-2 virus (hereinafter referred to as COVID-19) was announced by WHO in February 2020. In the Moscow Region (MR), the first case of the disease was detected on March 7, 2020 in a woman who arrived from Switzerland. Four weeks later, a rapid rise began, the peak of which fell on the 20th week (May 11, 2020 – May 17, 2020), which was replaced by a gradual steady decline that lasted for 13 weeks. Objective. To determine the level and structure of population immunity to the SARS-CoV-2 virus among the population of the Moscow Region between June 22, 2020 and July 11, 2020. Patients and methods. A serological study of seroprevalence among residents of MR to COVID-19 was carried out from June 22, 2020 till July 11, 2020 during the period of a steady decline in the incidence. The work was conducted as part of the first stage of the large-scale Rospotrebnadzor program to assess population immunity to the COVID-19 virus among the population of the Russian Federation. Volunteers for the study were selected by the method of questioning and randomization. The analysis included the results of a survey of 2688 people. The number of volunteers in all age groups was equal. The content of specific IgG to the COVID-19 nucleocapsid was determined by the enzyme-linked immunosorbent assay using a test system manufactured by the FBIS SRCAMB according to the manufacturer's instructions. Results. The results of the study showed that the collective immunity of the total population of the Moscow Region was 21.0%. The maximum level of population immunity was established in children aged 14–17 years (30.7%) and 1–6 years old (25.2%). There were no statistically significant differences in the level of seroprevalence between men and women. As a result of seroepidemiological research, it was shown that in the medical center, in the presence of contacts with patients with COVID-19, the risk of infection increases by 2.5 times. After infection with COVID-19, antibodies were detected in 78.7% of cases. In persons with a positive result of the PCR analysis obtained earlier, antibodies were detected in 82.8% of cases. A high proportion of asymptomatic infection among seropositive volunteers was found, which amounted to 83.4%. Key words: coronaviruses, SARS-CoV-2, incidence, seroprevalence, the Moscow Region, population, COVID-19
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.